NeOnc Targets Major Brain Cancer Trial Expansion with 500 Patients Across 30 Hospitals in Three Countries
NeOnc Technologies outlined plans for an international trial of NEO100 targeting approximately 500 patients across 30 hospitals in three countries, discussed on a Fox Business segment. NEO100 uses intranasal delivery to bypass the blood-brain barrier, with patient selection focused on IDH-mutation characteristics; prior clinical updates reported radiographic remission in six of 25 patients (24%).
Key figures
- Drug Name
- NEO100
- Planned patients
- 500
- Planned countries
- 3
- Planned hospitals
- 30
- Remission patients
- 6 of 25
- Reported remission rate
- 24%
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.